Sage Journals: Discover world-class research

Abstract

Background

Suboptimal use of cardiovascular prevention medications has been reported. We report recent trends in secondary cardiovascular disease prevention drug use in Europe.

Design

We used the 2004-2013 data from the Survey of Health, Ageing and Retirement in Europe (SHARE), a large longitudinal cohort study in middle-aged and elderly Europeans.

Methods

Cross-sectional and panel data logistic regression models were used to study trends in cholesterol- and blood pressure-lowering drug use and effects of participant characteristics on the likelihood of drug use among participants with histoty of cardiovascular disease in SHARE.

Results

In SHARE 21,388 participants reported history of cardiovascular disease and provided data on cholesterol- and blood pressure-lowering drug use. At initial report, 40% and 60% of them used cholesterol- or blood pressure-lowering drugs, respectively. Increasing cross-sectional time trends were observed for both medication classes (odds ratios of use in 2013 vs. 2004, 1.6 (95% confidence interval 1.4–1.7) and 1.5 (1.4–1.6), respectively). However, among participants with multiple observations, the use of both classes declined over time (2013 vs. 2004 odds ratio 0.63 (0.51–0.77) and 0.68 (0.55–0.84), respectively; both trend p < 0.001), and with increasing duration since last cardiovascular event (odds ratio 0.74 (0.60–0.91), trend p = 0.01 and odds ratio 0.82 (0.66–1.03), trend p = 0.06, respectively for durations of nine years or more versus less than one year). Among people with history of cardiovascular disease, those obese, retired or with hypercholesterolaemia, hypertension, worse self-perceived health, and, in the case of lipid-lowering medication, with diabetes, were more likely to use these medications.

Conclusions

Despite moderately increasing cross-sectional time trends, the use of secondary cardiovascular disease prevention drugs remains low in Europe with substantial discontinuation over time and with increasing duration from an acute cardiovascular event.

Keywords

Cardiovascular disease cholesterol-lowering drug therapy blood pressure drug therapy medication compliance

Get full access to this article

View all access options for this article.

References

Kernan

Ovbiagele

Black

et al.

Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160–2236.

Perk

De Backer

Gohlke

et al.

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

Mamdani

Alter

. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA 2004; 291: 1864–1870.

Yusuf

Islam

Chow

et al.

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011; 378: 1231–1243.

Kotseva

Wood

De Bacquer

et al.

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

Koopman

Vaartjes

Heintjes

et al.

Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur Heart J 2013; 34: 3198–3205.

Murphy

Simpson

MacIntyre

et al.

Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: Age, sex and socioeconomic disparities: A population-based study. Heart 2006; 92: 1047–1054.

Kolandaivelu

Leiden

O’Gara

et al.

Non-adherence to cardiovascular medications. Eur Heart J 2014; 35: 3267–3276.

Borsch-Supan

Brandt

Hunkler

et al.

Data resource profile: the Survey of Health, Ageing and Retirement in Europe (SHARE). Int J Epidemiol 2013; 42: 992–1001.

10.

World Bank. GNI per capita, PPP (current international $). World Development Indicators. International Comparison Program database, Washington: The World Bank Group, 2015.

11.

George

Judge

WEG

Carter Hill

et al.

The theory and practice of econometrics, 2nd ed. New York: Wiley, 1985.

12.

Hausman

. Specification tests in econometrics. Econometrica 1978; 46: 1251–1271.

13.

Stone

Robinson

Lichtenstein

et al.

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.

14.

Mancia

Fagard

Narkiewicz

et al.

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.

15.

Morris

Ballantyne

Birtcher

et al.

Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol 2014; 64: 196–206.

16.

Kjeldsen

Feldman

Lisheng

et al.

Updated national and international hypertension guidelines: A review of current recommendations. Drugs 2014; 74: 2033–2051.

17.

Kotseva

Ryden

De Backer

et al.

EURObservational research programme: EUROASPIRE. Eur Heart J 2015; 36: 950–951.

18.

Chen

Zhang

et al.

Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. Int J Cardiol 2014; 172: 88–95.

19.

Johansen

Green

Sen

et al.

Cardiovascular risk and statin use in the United States. Ann Fam Med 2014; 12: 215–223.

20.

Kotseva

Wood

De Backer

et al.

EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.

21.

Jackevicius

Mamdani

. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462–467.

22.

Benner

Glynn

Mogun

et al.

Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–461.

23.

Nieuwlaat

Wilczynski

Navarro

et al.

Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 11: Cd000011–Cd000011.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.62 MB

Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004–2013 Europe

Abstract

Background

Design

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material